NDARECTALENEMAPriority Review
Approved
Jan 1966
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
CORTENEMA (hydrocortisone) by ANI Pharmaceuticals is corticosteroid hormone receptor agonists [moa]. Approved for ulcerative colitis, adrenal insufficiency, congenital adrenal hyperplasia. First approved in 1966.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CORTENEMA is a rectal enema formulation of hydrocortisone, a corticosteroid hormone receptor agonist used primarily for ulcerative colitis and other inflammatory conditions. The drug works by suppressing local and systemic immune and inflammatory responses. It is administered rectally to deliver anti-inflammatory effects directly to the colon.
$0.007BPart D
LOE ApproachingMinimal Medicare Part D volume and declining lifecycle stage suggest limited team expansion; focus likely on maintenance and generic transition planning.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications (3)
Worked on CORTENEMA at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.